

17 Reference List

- 1 Cox, B. D. Blood pressure and respiratory function 1987. *In: The health and lifestyle survey. Preliminary report of a nationwide survey of the physical and mental health, attitudes and lifestyle of a random sample of 9003 British adults.* Health Promotion Research Trust , 17-33. London.
Ref ID: 19416
- 2 Renwick, D. S. and Connolly, M. J. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. *Thorax*.1996; 51(2): 164-168.
Ref ID: 19450
- 3 Seamark DA, Williams S, Timon S, Ward A, Ward D, Seamark C *et al.* Home or surgery based screening for chronic obstructive pulmonary disease (COPD)? *Primary Care Respiratory Journal* 2001;**10**:30-3.
Ref ID: 1184
- 4 Pride NB, Soriano JB. Chronic obstructive pulmonary disease in the United Kingdom: trends in mortality, morbidity and smoking. *Current Opinion in Pulmonary Medicine* 2002;**8**:95-101.
Ref ID: 19417
- 5 Office for National Statistics. *Health Statistics Quarterly*. 8. 2000. London, HMSO.
Ref ID: 19418
- 6 Soriano JB, Maier WC, Egger P, Visick G, Thakrar B, Sykes J *et al.* Recent trends in physician diagnosed COPD in women and men in the UK. *Thorax* 2000;**55**:789-94.
Ref ID: 105
- 7 Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med* 2000;**160**:1683-9.
Ref ID: 19246
- 8 Office for National Statistics. Mortality statistics: Cause, 1999. DH2 (No 26). 2000. London. HMSO.
Ref ID: 19419
- 9 Office for National Statistics. Living in London. Results from the 1998 General Household Survey. 2000. London. HMSO
Ref ID: 19420
- 10 Damiani M. Dixon J. Managing the pressure. Emergency hospital admissions in London 1997 - 2001. 2002. London. Kings Fund.
Ref ID: 19421
- 11 Anderson, R. H., Esmail, A., and Hollowell, J. Epidemiologically based needs assessment: Report 16: lower respiratory disease. 2003. London, Department of Health.
Ref ID: 19422
- 12 Office of Population Census and Surveys. Morbidity Statistics from General Practice. Fourth national study 1991 - 1992. 1995. London, HMSO.
Ref ID: 19423
- 13 Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. *Respir Med* 2003;**97 Suppl C**:S71-S79.
Ref ID: 19251
- 14 Eccles, M. and Mason, J. How to develop cost-conscious guidelines. *Health Technology Assessment*. Vol. 5. 16: 1-69. 2001.
Ref ID: 19424
- 15 National Institute for Clinical Excellence. Information for National Collaborating Centres and Guideline Development Groups. 2001. The Guideline Development Process series No 3. 2001. London. National Institute for Clinical Excellence.
Ref ID: 2038

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 16 Scottish Intercollegiate Guidelines Network. SIGN 50 A guideline developers' handbook. 2001. SIGN.
Ref ID: 19457
- 17 Murphy, M. K., Black, N. A., Lamping, D. L., McKee, C. M., Sanderson, C. F., and Askham, J. et al. Consensus development methods, and their use in clinical guideline development. *Health Technology Assessment*. Vol. 2. 1998.
Ref ID: 19425
- 18 National Institute for Clinical Excellence. Information for National Collaborating Centres and Guideline Development Groups. The Guideline Development Process Series No. 3., 1-65. 2003. London. National Institute for Clinical Excellence.
Ref ID: 19426
- 19 Fletcher CM, Elmes PC, Fairbairn MB, Wood CH. The Significance of Respiratory Symptoms and the Diagnosis of Chronic Bronchitis in a Working Population. *British Medical Journal* 1959;**2**:257-66.
Ref ID: 1269
- 20 Quanjer PH, Tammeling GJ, Cotes JE, Pederson OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. *Eur Respir J Suppl* 1993;**16**:5-40.
Ref ID: 19247
- 21 Nolan D, White P, Pearson MG. FEV-1 and PEF in COPD management. *Thorax* 1999;**54**:468-9.
Ref ID: 12121
- 22 Jones PW. Health status measurement in chronic obstructive pulmonary disease. *Thorax* 2001;**56**:880-7.
Ref ID: 8033
- 23 Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1986;**133**:14-20.
Ref ID: 628
- 24 Burrows B. The course and prognosis of different types of chronic airflow limitation in a general population sample from Arizona: comparison with the Chicago "COPD" series. *Am Rev Respir Dis* 1989;**140**:S92-S94.
Ref ID: 2373
- 25 COPD Guidelines Group of the Standards of Care Committee of the BTS. BTS guidelines for the management of chronic obstructive pulmonary disease. *Thorax* 1997;**52**:S1-28.
Ref ID: 3490
- 26 Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. 2001.
Ref ID: 54
- 27 British Thoracic Society, Scottish Intercollegiate Guideline Network. British Guideline on the management of asthma. *Thorax* 2003;**58**:1-94.
Ref ID: 19459
- 28 Calverley PMA, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. *Thorax* 2003;**58**:659-64.
Ref ID: 19248
- 29 Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1986;**133**:814-9.
Ref ID: 626
- 30 Nisar M, Walshaw M, Earis JE, Pearson MG, Calverley PM. Assessment of reversibility of airway obstruction in patients with chronic obstructive airways disease. *Thorax* 1990;**45**:190-4.
Ref ID: 1212
- 31 Nisar M, Earis JE, Pearson MG, Calverley PM. Acute bronchodilator trials in chronic obstructive pulmonary disease. *Am Rev Respir Dis* 1992;**146**:555-9.
Ref ID: 12080

- 32 Hadcroft J, Calverley PM. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. *Thorax* 2001;**56**:713-20.
Ref ID: 6526
- 33 Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, Dekhuijzen PN *et al*. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. *Thorax* 1992;**47**:429-36.
Ref ID: 2009
- 34 Tweeddale PM, Alexander F, Mchardy GJR. Short-term variability in fev1 and bronchodilator responsiveness in patients with obstructive ventilatory defects. *Thorax* 1987;**42**:487-90.
Ref ID: 1221
- 35 Fabbri, L. M., Romagnoli, M., Corbetta, L., Casoni, G., Busljetic, K., and Turato, G. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. *Journal of Respiratory Critical Care Medicine* 167(3), 418-424. 2003.
Ref ID: 19478
- 36 Santus P, Pecchiari M, Carlucci P, Boveri B, Di Marco F, Castagna F *et al*. Bronchodilation test in COPD: effect of inspiratory manoeuvre preceding forced expiration. *European Respiratory Journal*. 2003;**21**:82-5.
Ref ID: 19479
- 37 Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. *Thorax* 2003;**58**:1-5.
Ref ID: 1791
- 38 Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001;**163**:1256-76.
Ref ID: 12738
- 39 Freeman D. COPD prevalence in asymptomatic smokers - The first 100. *Prim Care Respir J* 2000;**9**:41.
Ref ID: 5414
- 40 van Schayck CP, Loozen JM, Wagena E, Akkermans RP, Wesseling GJ. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. *BMJ* 2002;**324**:1370-4.
Ref ID: 19249
- 41 Humerfelt S, Eide G, Aaro L, Gulsvik A. Effectiveness of postal smoking cessation advice: a randomised controlled trial in young men with reduced FEV1 and asbestos exposure. *Eur Respir J* 1998;**11**:284-90.
Ref ID: 1285
- 42 Risser NL, Belcher DW. Adding spirometry, carbon-monoxide, and pulmonary symptom results to smoking cessation counseling - a randomized trial. *Journal of General Internal Medicine* 1990;**5**:16-22.
Ref ID: 1241
- 43 Jonsson JS, Gislason T, Gislason D, Sigurdsson JA. Acute bronchitis and clinical outcome three years later: prospective cohort study. *BMJ* 1998;**317**:1433.
Ref ID: 8066
- 44 BTS. BTS guidelines for the management of COPD. The COPD Guidelines Group of the Standards of Care Committee of the BTS. *Thorax* 52(Suppl 5), S1-28. 1997.
Ref ID: 57
- 45 van der Meer RM, Wagena EJ, Ostelo RWJG, Jacobs JE, van Schayck CP. Smoking cessation for chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 19361
- 46 Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS *et al*. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. *JAMA* 1994;**272**:1497-505.
Ref ID: 998

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 47 Brandt CJ, Ellegaard H, Joensen M, Kallan FV, Sorknaes AD, Tougaard L. Effect of diagnosis of "smoker's lung". RYLUNG Group. *Lancet* 1997;**349**:253.
Ref ID: 984
- 48 Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients. *Psychopharmacology* 1995;**119**:193-204.
Ref ID: 992
- 49 Pederson LL, Wanklin JM, Lefcoe NM. The effects of counseling on smoking cessation among patients hospitalized with chronic obstructive pulmonary disease: a randomized clinical trial. *International Journal of the Addictions* 1991;**26**:107-19.
Ref ID: 1010
- 50 Tashkin, D., Kanner, R., Bailey, W. *et al.* Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. *Lancet* 2001;**357**:1571-5.
Ref ID: 977
- 51 Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS *et al.* Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease - The Lung Health Study. *American Journal of Respiratory and Critical Care Medicine* 2000;**161**:381-90.
Ref ID: 166
- 52 Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. *American Journal of Medicine* 1999;**106**:410-6.
Ref ID: 979
- 53 National Institute for Clinical Excellence. Guidance on the use of Nicotine Replacement Therapy (NRT) and bupropion for smoking cessation. NICE Technology Appraisal Guidance No 39. 2002. London. National Institute for Clinical Excellence.
Ref ID: 1150
- 54 Woolacott, N. F., Jones, L., Forbes, C. A., Mather, L. C., Sowden, A. J., Song, F. J., Raftery, J. P., Aveyard, P. N., Hyde, C. J., and Barton, P. M. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation. *Health Technology Assessment* 6(16), 1-245. 2002.
Ref ID: 19250
- 55 Corris PA, Neville E, Narimans, Gibson GJ. Dose-response study of inhaled salbutamol powder in chronic air-flow obstruction. *Thorax* 1983;**38**:292-6.
Ref ID: 170
- 56 Teale C, Morrison JFJ, Page RL, Pearson SB. Dose-response to inhaled salbutamol in chronic obstructive airways disease. *Postgraduate Medical Journal* 1991;**67**:754-6.
Ref ID: 183
- 57 Sestini P, Renzoni E, Robinson S, Poole P, Ram F.S.F. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 819
- 58 Dullinger D, Kronenberg R, Niewoehner DE. Efficacy of inhaled metaproterenol and orally-administered theophylline in patients with chronic airflow obstruction. *Chest*. 1986;**89**:171-3.
Ref ID: 317
- 59 Guyatt GH, Townsend M, Pugsley SO, Keller JL, Short HD, Taylor DW *et al.* Bronchodilators in chronic air-flow limitation. Effects of airway function, exercise capacity, and quality of life. *American Review of Respiratory Disease* 1987;**135**:1069-74.
Ref ID: 575
- 60 Guyatt GH, Townsend M, Nogradi S, Pugsley SO, Keller JL, Newhouse MT. Acute response to bronchodilator. An imperfect guide for bronchodilator therapy in chronic airflow limitation. *Archives of Internal Medicine* 1988;**148**:1949-52.
Ref ID: 1760

- 61 Guyatt GH, Townsend M, Keller JL, Singer J. Should study subjects see their previous responses: data from a randomized control trial. *Journal of Clinical Epidemiology* 1989;**42**:913-20.
Ref ID: 521
- 62 Hansen NC, May O. Domiciliary nebulised terbutaline in severe chronic airways obstruction. *European Respiratory Journal* 1990;**3**:463-4.
Ref ID: 19429
- 63 Jaeschke R, Guyatt GH, Singer J, Keller J, Newhouse MT. Mechanism of bronchodilator effect in chronic airflow limitation. *Canadian Medical Association Journal* 1991;**144**:35-9.
Ref ID: 19427
- 64 Klock LE, Miller TD, Morris AH, Watanabe S, Dickman MA. A comparative study of atropine sulphate and isoproterenol hydrochloride in chronic bronchitis. *American Review of Respiratory Disease* 1975;**112**:371-6.
Ref ID: 19430
- 65 Light RW, Summer WR, Luchsinger PC. Response of patients with chronic obstructive lung disease to the regular administration of nebulised isoproterenol. *Chest* 1975;**67**:634-9.
Ref ID: 19431
- 66 Shah SS, Johnson D, Woodcock AA, Johnson M, Geddes DM. Breathlessness and exercise tolerance in chronic airflow obstruction: 2-hourly versus 4-hourly salbutamol by inhalation. *Current Medical Research and Opinion* 1983;**8**:345-9.
Ref ID: 19432
- 67 Silins RA, Marlin GE. Evaluation of domiciliary treatment with terbutaline by wet nebulisation in patients with chronic bronchitis and emphysema. *Australian and New Zealand Journal of Medicine* 1985;**15**:230-40.
Ref ID: 19433
- 68 Tandon MK, Kailis SG. Bronchodilator treatment for partially reversible chronic obstructive airways disease. *Thorax* 1991;**46**:248-51.
Ref ID: 496
- 69 Taylor DR, Buick B, Kinney C. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible airflow obstruction. *American Review of Respiratory Disease* 1985;**131**:747-51.
Ref ID: 657
- 70 Wilson RSE, Connellan SJ. Domiciliary nebulized salbutamol solution in severe chronic airway obstruction in severe chronic airway obstruction. *Thorax* 1980;**35**:873-6.
Ref ID: 846
- 71 Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P *et al*. Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 2001;**163**:85-90.
Ref ID: 129
- 72 Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. *Chest* 1989;**96**:984-7.
Ref ID: 6307
- 73 Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable copd - comparison with ipratropium bromide alone. *Chest* 1995;**107**:401-5.
Ref ID: 188
- 74 Ikeda A, Nishimura K, Koyama H, Izumi T. Comparative dose-response study of 3 anticholinergic agents and fenoterol using a metered-dose inhaler in patients with chronic obstructive pulmonary-disease. *Thorax* 1995;**50**:62-6.
Ref ID: 157

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 75 Higgins BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway caliber and bronchial reactivity in asthma and chronic-bronchitis. *European Respiratory Journal* 1991;**4**:415-20.
Ref ID: 150
- 76 Braun SR, Mckenzie WN, Copeland C, Knight L, Ellerseick M. A comparison of the effect of ipratropium and albuterol in the treatment of chronic obstructive airway disease. *Archives of Internal Medicine* 1989;**149**:544-7.
Ref ID: 545
- 77 Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. *Archives of Internal Medicine*. 1999. 159(2):156-60.
Ref ID: 826
- 78 Colice GL. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease. *American Journal of Medicine*. 1996;**100**(1):11-18.
Ref ID: 326
- 79 Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: A retrospective analysis of data from seven clinical trials. *Chest* 1996;**110**:62-70.
Ref ID: 301
- 80 Taylor J, Kotch A, Rice K, Ghafouri M, Kurland CL, Fagan NA *et al*. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. *Chest* 2001;**120**:1253-61.
Ref ID: 156
- 81 Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M *et al*. Use of a long-acting inhaled beta(2)-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 2001;**163**:1087-92.
Ref ID: 173
- 82 Dahl R, Greefhorst LAPM, Nowak D, Nonikov V, Byrne AM, Thomson MH *et al*. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 2001;**164**:778-84.
Ref ID: 171
- 83 Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME *et al*. Efficacy of salmeterol xinafoate in the treatment of COPD. *Chest* 1999;**115**:957-65.
Ref ID: 37
- 84 Appleton S, Smith B, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease.(Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 1137
- 85 Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). [erratum appears in *Eur Respir J* 1997 Jul;10(7):1696.]. *European Respiratory Journal* 1997;**10**:815-21.
Ref ID: 252
- 86 Goodwin, B., Cox, F., Anderson, W., Wisniewski, M., and Rickard, K. Comparison of salmeterol 42ug BID (SLG) versus ipratropium bromide 36ug q.i.d. vs placebo on disease specific quality of life in COPD patients: reversible or non-reversible to ventolin. *ALA/ATS Abstract* 1997-1999 . 1997.
Ref ID: 19475
- 87 Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG *et al*. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. *Thorax* 1996;**51**:689-93.
Ref ID: 265
- 88 Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. *American Journal of Respiratory and Critical Care Medicine* 1997;**155**:1283-9.
Ref ID: 180

- 89 Rutten-Van M, Roos B, van N. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. *Thorax*. 1999;**54**:995-1003.
Ref ID: 968
- 90 Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. *Thorax* 1995;**50**:750-4.
Ref ID: 278
- 91 van Noord JA, de Munck DRAJ, Bantje TA, Hop WCJ, Akveld MLM, Bommer AL. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. *European Respiratory Journal* 2000;**15**:878-85.
Ref ID: 175
- 92 Shukla, V. K., Husereau, D. R., Boucher, M., Mensunkai, S., and Dales, R. Long-acting beta2-agonists for maintenance therapy of stable chronic obstructive pulmonary disease: a systematic review. 39. 2002. Ottawa, Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
Ref ID: 1764
- 93 Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P *et al*. Formoterol in patients with chronic obstructive pulmonary disease: A randomized, controlled, 3-month trial. *European Respiratory Journal* 2002;**19**:936-43.
Ref ID: 249
- 94 Rossi A, Kristufek P, Levine BE, Thomson MH, Till D, Kottakis J *et al*. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. *Chest* 2002;**121**:1058-69.
Ref ID: 966
- 95 Brusasco V, Hodder R, Miravittles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. *Thorax* 2003;**58**:399-404.
Ref ID: 1790
- 96 Mahler DA, Wire P, Horstman D, Chang C-N, Yates J, Fischer T *et al*. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 2002;**166**:1084-91.
Ref ID: 1689
- 97 Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S *et al*. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. [Erratum in *Eur Respir J* 2003;**21**:912]. *European Respiratory Journal* 2003;**21**:74-81.
Ref ID: 1698
- 98 Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A *et al*. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial. *Lancet* 2003;**361**:449-56.
Ref ID: 1702
- 99 Donohue JF, van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ *et al*. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. *Chest* 2002;**122**:47-55.
Ref ID: 137
- 100 Littner MR, Ilowite JS, Tashkin DP, Friedman M, Serby CW, Menjoge SS *et al*. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 2000;**161**:1136-42.
Ref ID: 176
- 101 Casaburi R, Briggs DD, Donohue JF, Serby CW, Menjoge SS, Witek TJ. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD - A 13-week multicenter trial. *Chest* 2000;**118**:1294-302.
Ref ID: 174

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 102 Casaburi R, Mahler DA, Jones PW, Wanner A, San Pedro G, ZuWallack RL *et al*. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. *European Respiratory Journal* 2002;**19**:217-24.
Ref ID: 34
- 103 Vincken W, van Noord JA, Greefhorst APM, Bantje TA, Kesten S, Korducki L *et al*. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. *European Respiratory Journal* 2002;**19**:209-16.
Ref ID: 33
- 104 Vassallo R, Lipsky JJ. Theophylline: recent advances in the understanding of its mode of action and uses in clinical practice. *Mayo Clinic Proceedings* 1998;**73**:346-54.
Ref ID: 19434
- 105 Murciano D, Aubier M, Lecocguic Y, Pariente R. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. *N Engl J Med* 1984;**311**:349-53.
Ref ID: 19435
- 106 Ziment I. Theophylline and mucociliary clearance. *Chest* 1987;**92**:38S-43S.
Ref ID: 19436
- 107 Matthay RA, Mahler DA. Theophylline improves global cardiac function and reduces dyspnea in chronic obstructive lung disease. *Journal of Allergy & Clinical Immunology* 1986;**78**:793-9.
Ref ID: 1758
- 108 Upton RA. Pharmacokinetic interactions between theophylline and other medication. *Clin Pharmacokinet* 1991;**20**:66-80.
Ref ID: 19437
- 109 Aronson JK, Hardman M, Reynolds DJ. ABC of monitoring drug therapy. Theophylline. *BMJ* 1992;**305**:1355-8.
Ref ID: 708
- 110 Ram FSF, Jones PW, Castro AA, De Brito JA, Atallah AN, Lacasse Y *et al*. Oral theophylline for chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library*. Oxford: Update Software 2003; **Issue 3**.
Ref ID: 1713
- 111 Fink G, Kaye C, Sulkes J, Gabbay U, Spitzer SA. Effect of theophylline on exercise performance in patients with severe chronic obstructive pulmonary disease. *Thorax* 1994;**49**:332-4.
Ref ID: 1737
- 112 Newman D, Tamir J, Speedy L, Newman JP, Ben Dov I. Physiological and neuropsychological effects of theophylline in chronic obstructive pulmonary disease. *Israel Journal of Medical Sciences* 1994;**30**:811-6.
Ref ID: 1748
- 113 Alexander MR, Dull WL, Kasik JE. Treatment of chronic obstructive pulmonary disease with orally administered theophylline. A double-blind, controlled study. *Journal of the American Medical Association* 1980;**244**:2286-90.
Ref ID: 1731
- 114 Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. *American Review of Respiratory Disease* 1993;**148**:1030-6.
Ref ID: 1745
- 115 Compton CH, Gubb J, Nieman R, Edelson J, Amit O, Bakst A *et al*. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. *Lancet* 2001;**358**:265-70.
Ref ID: 1261
- 116 Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. *Am J Respir Crit Care Med* 1997;**155**:542-8.
Ref ID: 8391

- 117 Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. *Am J Respir Crit Care Med* 2002;**165**:1592-6.
Ref ID: 6796
- 118 Peperell K, Rudolf M, Pearson M, Diggle J. General practitioner prescribing habits in asthma/COPD. *Asthma in General Practice* 1997;**5**:29-30.
Ref ID: 19287
- 119 Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials. *American Journal of Medicine* 2002;**113**:59-65.
Ref ID: 1668
- 120 Burge PS, Calverley PMA, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *British Medical Journal* 2000;**320**:1297-303.
Ref ID: 194
- 121 The Lung Health Study Research Group, Altose MD, Redline S, Deitz CD, Quinlan KJ, Eichenhorn MS *et al*. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *New England Journal of Medicine* 2000;**343**:1902-9.
Ref ID: 193
- 122 Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. *Lancet* 1999;**353**:1819-23.
Ref ID: 196
- 123 Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB *et al*. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. *New England Journal of Medicine* 1999;**340**:1948-53.
Ref ID: 195
- 124 van Grunsven PM, van Schayck CP, Derenne JP, Kerstjens HA, Renkema TE, Postma DS *et al*. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. *Thorax* 1999;**54**:7-14.
Ref ID: 879
- 125 Derenne, J. P. Effects of high dose inhaled beclomethasone in the rate of decline in FEV1 in patients with chronic obstructive pulmonary disease: results of a 2 year prospective multicentre study. *Am J Respir Crit Care Med* 151. 1995.
Ref ID: 19463
- 126 Johnell O, Pauwels R, Lofdahl C-G, Laitinen LA, Postma DS, Pride NB *et al*. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. *European Respiratory Journal* 2002;**19**:1058-63.
Ref ID: 1711
- 127 Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. *Eur Respir J* 2003;**21**:68-73.
Ref ID: 1787
- 128 Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. *European Respiratory Journal* 2002;**20**:819-25.
Ref ID: 1265
- 129 Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001; **164**:580-4.
Ref ID: 19458
- 130 Sin DD, Man SFP. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: Does the dose matter? *European Respiratory Journal* 2003;**21**:260-6.
Ref ID: 19360

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 131 Renkema, T. E., Schouten, J. P., Koeter, G. H., and Postma, D. S. Effects of long-term treatment with corticosteroids in COPD. *Chest* 1996; **109**:1156-1162. 1996.
Ref ID: 19474
- 132 Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. *Lancet* 1998; **351**:773-80.
Ref ID: 197
- 133 Dragonetti ME, Groth ML. Inhaled corticosteroids in chronic obstructive pulmonary disease: Are they cost-effective? *Clinical-Pulmonary-Medicine* 2000; **7**.
Ref ID: 19314
- 134 Callahan CM, Dittus RS, Katz BP. Oral corticosteroid therapy for patients with stable chronic obstructive pulmonary disease. A meta-analysis. *Annals of Internal Medicine* 1991; **114**:216-23.
Ref ID: 99
- 135 Corden Z, Rees PJ. The effect of oral corticosteroids on bronchodilator responses in COPD. *Respiratory Medicine* 1998; **92**:279-82.
Ref ID: 1672
- 136 Weiner P, Weiner M, Rabner M, Waizman J, Magadle R, Zamir D. The response to inhaled and oral steroids in patients with stable chronic obstructive pulmonary disease. *Journal of Internal Medicine* 1999; **245**:83-9.
Ref ID: 1709
- 137 Weir DC, Robertson AS, Gove RI, Burge PS. Time course of response to oral and inhaled corticosteroids in nonasthmatic chronic air-flow obstruction. *Thorax* 1990; **45**:118-21.
Ref ID: 12
- 138 Weir DC, Gove RI, Robertson AS, Burge PS. Corticosteroid trials in non-asthmatic chronic airflow obstruction: A comparison of oral prednisolone and inhaled beclomethasone dipropionate. *Thorax* 1990; **45**:112-7.
Ref ID: 1710
- 139 Royal College of Physicians. Osteoporosis. Clinical guidelines for prevention and treatment. 1999. London. Royal College Physicians.
Ref ID: 19496
- 140 Chapman, Arvidsson PC. The addition of salmeterol 50 mg bid to anticholinergic treatment in patients with COPD: A randomized, placebo controlled trial. *Canadian Respiratory Journal* 2002; **9**:178-85.
Ref ID: 1719
- 141 Auerbach D, Hill C, Baughman R, Boyars M, Braun S, Buist AS *et al*. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. *Chest* 1997; **112**:1514-21.
Ref ID: 830
- 142 Bone R, Boyars M, Braun SR, Buist S, Campbell S, Chick T *et al*. In chronic obstructive pulmonary-disease, a combination of ipratropium and albuterol is more effective than either agent alone - an 85-day multicenter trial. *Chest* 1994; **105**:1411-9.
Ref ID: 182
- 143 Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S *et al*. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. *Respiration* 1998; **65**:354-62.
Ref ID: 827
- 144 D'Urzo AD, De S, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G *et al*. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study. *Chest* 2001; **119**:1347-56.
Ref ID: 973

- 145 Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ, Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. *Chest*. 1999;**115**:635-41.
Ref ID: 1720
- 146 ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K *et al*. Salmeterol plus theophylline combination therapy in the treatment of COPD. *Chest* 2001;**119**:1661-70.
Ref ID: 1118
- 147 Bellia V, Foresi A, Bianco S, Grassi V, Olivieri D, Bensi G *et al*. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). *Respiratory Medicine* 2002;**96**:881-9.
Ref ID: 1264
- 148 Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. *Chest*. 1995;**107**:718-23.
Ref ID: 1722
- 149 Brocklebank, D. M, Ram, F. S. F, Wright, J., Barry, P., Cates, C., and Davies, L. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. *Health Technology Assessment* 5(26). 2001.
Ref ID: 1374
- 150 Ram FSF, Brocklebank DM, Muers M, Wright J, Jones PW. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease.(Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 1375
- 151 Cuvelier A, Muir J, Benhamou D, Guerin J, Weitzenblum E, Zuck P *et al*. Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients. *Respiratory Care* 2002;**47**:159-66.
Ref ID: 1428
- 152 Eiser N, Angus K, McHale S. The role of domiciliary nebulizers in managing patients with severe COPD. *Respiratory Medicine*. 2001;**95**:265-74.
Ref ID: 1429
- 153 O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MCP, Bernstien A. A long-term prospective assessment of home nebulizer treatment. *Respiratory Medicine* 1992;**86** :317-25.
Ref ID: 1432
- 154 Allen SC. Competence thresholds for the use of inhalers in people with dementia *Age Ageing* 1997;**26**:83-6.
Ref ID: 19257
- 155 Hodkinson HM. Evaluation of a mental test score for assessment of mental impairment in the elderly. *Age Ageing* 1972;**1**:233-8.
Ref ID: 19255
- 156 Connolly MJ. Inhaler technique of elderly patients: comparison of metered-dose inhalers and large volume spacer devices. *Age and Ageing* 1995;**24**:190-2.
Ref ID: 3396
- 157 Allen SC, Prior A. What determines whether an elderly patient can use a metered dose inhaler correctly? *Br J Dis Chest* 1986;**80**:45-9.
Ref ID: 19258
- 158 Armitage JM, Williams SJ. Inhaler technique in the elderly. *Age Ageing* 1988;**17**:275-8.
Ref ID: 19259
- 159 Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. *Thorax* 1991;**46**:891-4.
Ref ID: 19261

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 160 Diggory P, Bailey R, Vallon A. Effectiveness of inhaled bronchodilator delivery systems for elderly patients. *Age Ageing* 1991;**20**:379-82.
Ref ID: 19263
- 161 Harvey J, Williams JG. Randomised cross-over comparison of five inhaler systems for bronchodilator therapy. *Br J Clin Pract* 1992;**46**:249-51.
Ref ID: 19262
- 162 Allen SC, Ragab S. Ability to learn inhaler technique in relation to cognitive scores and tests of praxis in old age. *Postgrad Med J* 2002;**78**:37-9.
Ref ID: 19256
- 163 Teale C, Jones A, Patterson CJ, Kearney MT, Stanners AJ, Muers MF. Community survey of home nebulizer technique by elderly people. *Age Ageing* 1995;**24**:276-7.
Ref ID: 16642
- 164 O'Driscoll BR. Nebulisers for chronic obstructive pulmonary disease. *Thorax* 1997;**52**:S49-S52.
Ref ID: 87
- 165 Boe J, Dennis JH, O'Driscoll BR, Bauer TT, Carone M, Dautzenberg B *et al*. European Respiratory Society Guidelines on the use of nebulizers. *Eur Respir J* 2001;**18**:228-42.
Ref ID: 19264
- 166 Formgren H, Sjobqvist A, Stahl E, Wiren JE. Terbutaline in COPD comparison between Turbuhaler and chlorofluorocarbon (CFC) inhaler. *Lung* 1994;**172**:271-80.
Ref ID: 1795
- 167 Ikeda A, Nishimura K, Koyama H, Tsukino M, Hajiro T, Mishima M *et al*. Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, and a jet nebulizer in patients with chronic obstructive pulmonary disease. *Respiration*. 1999;**66**:119-23.
Ref ID: 1440
- 168 Iacono P, Velicitat P, Guemas E, Leclerc V, Thebault JJ. Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. *Respiratory Medicine*. 2000;**94**:490-5.
Ref ID: 1439
- 169 Royal College of Physicians. Domiciliary oxygen therapy services. Clinical guidelines and advice for prescribers. London: Royal College of Physicians, 1999.
Ref ID: 19265
- 170 Crockett AJ, Cranston JM, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library*. Oxford: Update Software 2003;**Issue 3**.
Ref ID: 1799
- 171 Ram FSF, Wedzicha JA. Ambulatory oxygen for chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library*. Oxford: Update Software 2003;**Issue 3**.
Ref ID: 1796
- 172 Medical Research Council Working Party, Flenely DC. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. *Lancet* 1981;**1**:681-6.
Ref ID: 10882
- 173 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. *Ann Intern Med* 1980;**93** :391-8.
Ref ID: 12109
- 174 Timms RM, Khaja FU, Williams GW. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. *Ann Intern Med* 1985;**102**:29-36.
Ref ID: 16841

- 175 Cooper CB, Waterhouse J, Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. *Thorax* 1987;**42**:105-10.
Ref ID: 3471
- 176 Cooper CB, Howard P. An analysis of sequential physiologic changes in hypoxic cor pulmonale during long-term oxygen therapy. *Chest* 1991;**100**:76-80.
Ref ID: 19266
- 177 Zielinski J, MacNee W, Wedzicha J, Ambrosino N, Braghiroli A, Dolensky J *et al*. Causes of death in patients with COPD and chronic respiratory failure. *Monaldi Arch Chest Dis* 1997;**52**:43-7.
Ref ID: 19267
- 178 PPA. Drug Tariff National Health Service, England and Wales. The Stationary Office Books, 2003.
Ref ID: 19494
- 179 Heaney LG, McAllister D, MacMahon J. Cost minimisation analysis of provision of oxygen at home: are the drug tariff guidelines cost effective? *BMJ* 1999;**319** :19-23.
Ref ID: 19268
- 180 Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S *et al*. Ambulatory oxygen improves quality of life of COPD patients: A randomised controlled study. *European Respiratory Journal* 2002;**20**:306-12.
Ref ID: 19414
- 181 Crockett AJ, Cranston JM, Moss JR, Alpers JH. A review of long-term oxygen therapy for chronic obstructive pulmonary disease. *Respir Med* 2001;**95**:437-43.
Ref ID: 1797
- 182 Andersson A, Strom K, Brodin H, Alton M, Boman G, Jakobsson P *et al*. Domiciliary liquid oxygen versus concentrator treatment in chronic hypoxaemia: a cost-utility analysis. *Eur Respir J* 1998;**12**:1284-9.
Ref ID: 19269
- 183 Okubadejo AA, Paul EA, Wedzicha JA. Domiciliary oxygen cylinders: indications, prescription and usage. *Respir Med* 1994;**88**:777-85.
Ref ID: 12336
- 184 Woodcock AA, Gross ER, Geddes DM. Oxygen relieves breathlessness in "pink puffers"
Lancet 1981;**1**:907-9.
Ref ID: 19270
- 185 Evans TW, Waterhouse JC, Carter A, Nicholl JF, Howard P. Short burst oxygen treatment for breathlessness in chronic obstructive airways disease. *Thorax* 1986;**41**:611-5.
Ref ID: 4901
- 186 Swinburn CR, Mould H, Stone TN, Corris PA, Gibson GJ. Symptomatic benefit of supplemental oxygen in hypoxemic patients with chronic lung disease. *Am Rev Respir Dis* 1991;**143**:913-5.
Ref ID: 16419
- 187 Ambrosino N, Montagna T, Nava S, Negri A, Brega S, Fracchia C *et al*. Short term effect of intermittent negative pressure ventilation in COPD patients with respiratory failure. *Eur Respir J* 1990;**3**:502-8.
Ref ID: 498
- 188 Meecham Jones DJ, Paul EA, Jones PW, Wedzicha JA. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. *American Journal of Respiratory & Critical Care Medicine* 1995;**152**:538-44.
Ref ID: 1469
- 189 Plant PK, Elliott MW. Management of ventilatory failure in COPD. *Thorax* 2003;**58**:537-42.
Ref ID: 19274
- 190 Wijkstra PJ, Lacasse Y, Guyatt GH, Goldstein RS. Nocturnal non-invasive positive pressure ventilation for stable chronic obstructive pulmonary disease. [Cochrane Review]. *The Cochrane Library. Oxford: Update Software* 2003;**Issue 3**.
Ref ID: 1482

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 191 Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF *et al*. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. *European Respiratory Journal* 2002;**20**:529-38.
Ref ID: 1301
- 192 Behnke RH, Blount SG, Bristow JD, Carrieri V, Pierce JA, Sasahara A *et al*. Primary prevention of pulmonary heart disease. *Circulation* 1970;**41**:A17-A23.
Ref ID: 19276
- 193 Chetty KG, Brown SE, Light RW. Identification of pulmonary hypertension in chronic obstructive pulmonary disease from routine chest radiographs. *Am Rev Respir Dis* 1982;**126**:338-41.
Ref ID: 3056
- 194 Miller MR, Gorecka DM, Bishop JM. Radiological prediction of pulmonary hypertension in chronic obstructive pulmonary disease. *Eur Heart J* 1984;**5**:581-7.
Ref ID: 11143
- 195 Oswald-Mammosser M, Oswald T, Nyankiye E, Dickele MC, Grange D, Weitzenblum E. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. *Eur J Respir Dis* 1987;**71**:419-29.
Ref ID: 12469
- 196 MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One *Am J Respir Crit Care Med* 1994;**150**:833-52.
Ref ID: 19279
- 197 Weitzenblum E, Zielinski J, Bishop JM. The diagnosis of "cor pulmonale" by non-invasive methods: a challenge for pulmonologists and cardiologists. *Bull Eur Physiopathol.Respir* 1983;**19**:423-6.
Ref ID: 19280
- 198 Danchin N, Cornette A, Henriquez A, Godenir JP, Ethevenot G, Polu JM *et al*. Two-dimensional echocardiographic assessment of the right ventricle in patients with chronic obstructive lung disease. *Chest* 1987;**92**:229-33.
Ref ID: 3814
- 199 Starling MR, Crawford MH, Sorensen SG, O'Rourke RA. A new two-dimensional echocardiographic technique for evaluating right ventricular size and performance in patients with obstructive lung disease. *Circulation* 1982;**66**:612-20.
Ref ID: 15972
- 200 Turnbull LW, Ridgway JP, Biernacki W, McRitchie H, Muir AL, Best JJ *et al*. Assessment of the right ventricle by magnetic resonance imaging in chronic obstructive lung disease. *Thorax* 1990;**45**:597-601.
Ref ID: 17150
- 201 Altschule MD. Limited usefulness of the so-called ejection fraction measurement in clinical practice. *Chest* 1986;**90**:134-5.
Ref ID: 472
- 202 MacNee W, Morgan AD, Wathen CG, Muir AL, Flenley DC. Right ventricular performance during exercise in chronic obstructive pulmonary disease. The effects of oxygen. *Respiration* 1985;**48**:206-15.
Ref ID: 10067
- 203 Zielinski J, Hawrylkiewicz I, Gorecka D, Gluskowski J, Koscińska M. Captopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. *Chest* 1986;**90**:562-5.
Ref ID: 19282
- 204 Kiely DG, Cargill RI, Wheeldon NM, Coutie WJ, Lipworth BJ. Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. *Cardiovasc Res* 1997;**33**:201-8.
Ref ID: 8568

- 205 Saadjian AY, Philip-Joet FF, Vestri R, Arnaud AG. Long-term treatment of chronic obstructive lung disease by Nifedipine: an 18-month haemodynamic study. *Eur Respir J* 1988;**1**:716-20.
Ref ID: 14486
- 206 Johnson DC, Joshi RC, Mehta R, Cunnington AR. Acute and long term effect of nifedipine on pulmonary hypertension secondary to chronic obstructive airways disease. *Eur J Respir Dis Suppl* 1986;**146**:495-502.
Ref ID: 7959
- 207 Gould L, Zahir M, DeMartino A, Gomprecht RF. Haemodynamic effects of phentolamine in chronic obstructive pulmonary disease. *Br Heart J* 1971;**33**:445-50.
Ref ID: 6142
- 208 Van Mieghem W, De Backer G, De Wispelaere B, Billiet L, Cosemans J. Phentolamine infusion in cor pulmonale due to chronic obstructive pulmonary disease. *Acta Cardiol* 1978;**33**:253-62.
Ref ID: 19283
- 209 Vik-Mo H, Walde N, Jentoft H, Halvorsen FJ. Improved haemodynamics but reduced arterial blood oxygenation, at rest and during exercise after long-term oral prazosin therapy in chronic cor pulmonale. *Eur Heart J* 1985;**6**:1047-53.
Ref ID: 19284
- 210 Green LH, Smith TW. The use of digitalis in patients with pulmonary disease. *Ann Intern Med* 1977;**87**:459-65.
Ref ID: 6210
- 211 Jezek V, Schrijen F. Haemodynamic effect of deslanoside at rest and during exercise in patients with chronic bronchitis. *Br Heart J* 1973;**35**:2-8.
Ref ID: 7915
- 212 Brown SE, Pakron FJ, Milne N, Linden GS, Stansbury DW, Fischer CE *et al*. Effects of digoxin on exercise capacity and right ventricular function during exercise in chronic airflow obstruction. *Chest* 1984;**85**:187-91.
Ref ID: 2209
- 213 British Thoracic Society Standards of Care Subcommittee on Pulmonary Rehabilitation. Pulmonary rehabilitation. *Thorax* 2001;**56**:827-34.
Ref ID: 1223
- 214 Lacasse Y, Brosseau L, Milne S, Martin S, Wong E, Guyatt GH *et al*. Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease.(Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 1157
- 215 Ries AL, Carlin BW, Carrieri-Kohlman V, Casaburi R, Celli BR, Emery CF *et al*. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. *Chest* 1997;**112**:1363-96.
Ref ID: 63
- 216 Salman GF, Mosier MC, Beasley BW, Calkins DR. Rehabilitation for patients with chronic obstructive pulmonary disease: Meta-analysis of randomized controlled trials. *Journal of General Internal Medicine* 2003;**18**:213-21.
Ref ID: 19351
- 217 Toshima MT, Blumberg E, Ries AL, Kaplan RM. Does rehabilitation reduce depression in patients with chronic obstructive pulmonary disease? *Journal of Cardiopulmonary Rehabilitation* 1992;**12**:261-9.
Ref ID: 1024
- 218 Griffiths TLB. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial [published erratum appears in *Lancet* 2000 Apr 8;355(9211):1280]. *Lancet* 2000;**355**:362-8.
Ref ID: 1041

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 219 Ries AL, Kaplan RM, Limberg TMK, Prewitt LM. Effects of pulmonary rehabilitation on physiological and psychosocial outcomes in patients with chronic obstructive pulmonary-disease. *Annals of Internal Medicine* 1995;**122**:823-32.
Ref ID: 49
- 220 Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Longitudinal trends in exercise capacity and health status after pulmonary rehabilitation in patients with COPD. *Respiratory Medicine* 2003;**97**:173-80.
Ref ID: 19371
- 221 McBride A and Milne R. *Hospital based pulmonary rehabilitation programmes for patients with severe chronic obstructive pulmonary disease*. Southampton: Wessex Institute for Health Research and Development; 1999. Development and evaluation committee report number:94.
Ref ID: 19346
- 222 Griffiths TL, Phillips CJ, Davies S, Burr ML, Campbell IA. Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme. *Thorax* 2001;**56**:779-84.
Ref ID: 6262
- 223 Smith K, Cook D, Guyatt GH, Madhavan J, Oxman AD. Respiratory muscle training in chronic airflow limitation: a meta-analysis. *American Review of Respiratory Disease* 1992;**145**:533-9.
Ref ID: 894
- 224 Lotters F, van Tol B, Kwakkel G, Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. *European Respiratory Journal* 2002;**20**:570-6.
Ref ID: 1227
- 225 Ortega F, Toral J, Cejudo P, Villagomez R, Sanchez H, Castillo J *et al*. Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 2002;**166**:669-74.
Ref ID: 19373
- 226 Puente-Maestu L, Sanz ML, Sanz P, Cubillo JM, Mayol J, Casaburi R. Comparison of effects of supervised versus self-monitored training programmes in patients with chronic obstructive pulmonary disease. *European Respiratory Journal* 2000;**15**:517-25.
Ref ID: 1228
- 227 Berry MJ, Rejeski WJ, Adair NE, Ettinger Jr WH, Zaccaro DJ, Sevick MA. A randomized, controlled trial comparing long-term and short-term exercise in patients with chronic obstructive pulmonary disease. *Journal of Cardiopulmonary Rehabilitation* 2003;**23**:60-8.
Ref ID: 19370
- 228 Young P, Dewse M, Fergusson W, Kolbe J. Respiratory rehabilitation in chronic obstructive pulmonary disease: Predictors of nonadherence. *European Respiratory Journal* 1999;**13**:855-9.
Ref ID: 1040
- 229 Foglio K, Bianchi L, Ambrosino N. Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled study. *Chest* 2001;**119**:1696-704.
Ref ID: 1045
- 230 National Institute for Clinical Excellence. Guidance on the use of zanamivir, amantadine and oseltamivir for the treatment of influenza. NICE technology appraisal guidance- No.58. 2003. London. National Institute for Clinical Excellence.
Ref ID: 1789
- 231 Poole PJ, Chacko E, Wood-Baker RWB, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease.(Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 1523

- 232 Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. *Ann Intern Med* 1999;**130**:397-403.
Ref ID: 1724
- 233 National Institute of Clinical Excellence. Guidance on the use of Zanamivir (Relenza) in the treatment of influenza. NICE technology appraisal guidance- No.15. 2000. London. National Institute of Clinical Excellence.
Ref ID: 1715
- 234 Turner, D., Wailoo, A., Nicholson, K., Cooper, N., Sutton, A., Abrams, K., and NICE. Systematic Review and Economic Decision Modelling for the Prevention and Treatment of Influenza A and B. 28-4-2002. University of Leicester; ScHARR at University of Sheffield, NICE.
Ref ID: 1786
- 235 Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. *Archives of Internal Medicine* 1999;**159**:2437-42.
Ref ID: 216
- 236 Nichol KL. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. *Vaccine* 1999;**17 Suppl 1**:S91-S93.
Ref ID: 1723
- 237 Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. *Canadian Medical Association Journal* 1987;**136**:361-5.
Ref ID: 1620
- 238 Tandon MK, GebSKI V. A controlled trial of a killed Haemophilus influenzae vaccine for prevention of acute exacerbations of chronic bronchitis. *Australian & New Zealand Journal of Medicine* 1991;**21**:427-32.
Ref ID: 1618
- 239 Hak E, Van Essen GA, Buskens E, Stalman W, De Melker RA. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, the Netherlands. *Journal of Epidemiology and Community Health* 1998;**52**:120-5.
Ref ID: 108
- 240 Letter from the Chief Medical Officer, the Chief Nursing Officer and the Chief Pharmaceutical Officer. *Update on Immunisation issues*. PL/CMO/2003/4). 2003.
Ref ID: 19492
- 241 The Department of Health. Immunisation Against Infectious Disease ("The Green Book"). 1996. London. Department of Health.
Ref ID: 19286
- 242 The Department of Health. Pneumococcal (Draft Replacement Chapter). In: *Immunisation Against Infectious Disease ("The Green Book")*, London: Department of Health, 2003.
Ref ID: 19493
- 243 Snider GL. Reduction pneumoplasty for giant bullous emphysema. Implications for surgical treatment of nonbullous emphysema. *Chest* 1996;**109**:540-8.
Ref ID: 15767
- 244 Stirling GR, Babidge WJ, Peacock MJ, Smith JA, Matar KS, Snell GI *et al*. Lung volume reduction surgery in emphysema: a systematic review. *Ann Thorac Surg* 2001;**72**:641-8.
Ref ID: 16105
- 245 Pompeo E, Marino M, Nofroni I, Matteucci G, Mineo TC. Reduction pneumoplasty versus respiratory rehabilitation in severe emphysema: a randomized study. Pulmonary Emphysema Research Group. *Ann Thorac Surg* 2000;**70**:948-53.
Ref ID: 13344

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 246 National Emphysema Treatment Trial Research Group. A randomised trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. *The New England Journal of Medicine* 2003;**348**:2059-73.
Ref ID: 1788
- 247 National Emphysema Treatment Trial Research Group. Patients at high risk of death after lung-volume-reduction surgery. *N Engl J Med* 2001;**345**:1075-83.
Ref ID: 19288
- 248 Zenati M, Keenan RJ, Courcoulas AP, Griffith BP. Lung volume reduction or lung transplantation for end-stage pulmonary emphysema?
Eur J Cardiothorac.Surg 1998;**14**:27-31.
Ref ID: 19289
- 249 Gaissert HA, Trulock EP, Cooper JD, Sundaresan RS, Patterson GA. Comparison of early functional results after volume reduction or lung transplantation for chronic obstructive pulmonary disease. *J Thorac Cardiovasc Surg* 1996;**111**:296-306.
Ref ID: 5568
- 250 Keller CA, Naunheim KS, Osterloh J, Krucylak PE, Baudendistel L, McBride L *et al.* Hemodynamics and gas exchange after single lung transplantation and unilateral thoracoscopic lung reduction. *J Heart Lung Transplant* 1997;**16**:199-208.
Ref ID: 8421
- 251 Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. *J Heart Lung Transplant* 2001;**20**:805-15.
Ref ID: 7305
- 252 Cassivi SD, Meyers BF, Battafarano RJ, Guthrie TJ, Trulock EP, Lynch JP *et al.* Thirteen-year experience in lung transplantation for emphysema. *Ann Thorac Surg* 2002;**74**:1663-9.
Ref ID: 2726
- 253 American Thoracic Society, Aris R, Barbers RG, Barst R, Baz MA, de Boer W *et al.* International guidelines for the selection of lung transplant candidates. *Am J Respir Crit Care Med* 1998;**158**:335-9.
Ref ID: 513
- 254 Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J *et al.* Effect of lung-volume-reduction surgery in patients with severe emphysema. *New England Journal of Medicine* 2000;**343**:239-45.
Ref ID: 227
- 255 Trulock EP, III. Lung Transplantation for COPD. *Chest* 1998;**113**(4):269S-276S.
Ref ID: 17086
- 256 Eriksson S. A 30-year perspective on alpha(1)-antitrypsin deficiency. *Chest* 1996;**110**:S237-S242.
Ref ID: 144
- 257 Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DCS, Ulrik CS *et al.* A randomized clinical trial of alpha1-antitrypsin augmentation therapy. *American Journal of Respiratory & Critical Care Medicine* 1999;**160**:1468-72.
Ref ID: 1249
- 258 The Alpha 1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha 1-antitrypsin. *American Journal of Respiratory & Critical Care Medicine* 1998;**158**:49-59.
Ref ID: 1336
- 259 Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok JA *et al.* Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? *European Respiratory Journal* 1997;**10**:2260-3.
Ref ID: 1258
- 260 Hay JW, Robin ED. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. *American Journal of Public Health* 1991;**81**:427-33.
Ref ID: 1253

- 261 Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library*. Oxford: Update Software 2003; Issue 3.
Ref ID: 100
- 262 Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. *Clinical Therapeutics* 2000;22:209-21.
Ref ID: 874
- 263 Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review. *European Respiratory Journal* 2000;16:253-62.
Ref ID: 923
- 264 Cattaneo C. Neltexine tablets in smoking and non-smoking patients with COPD. A double-blind, randomised, controlled study versus placebo. *Minerva Medica*. 2001;92:277-84.
Ref ID: 1421
- 265 Gerrits CMJM, Herings RMC, Leufkens HGM, Lammers JWJ. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. *Eur Respir J* 2003;21:795-8.
Ref ID: 1794
- 266 Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. *BMJ* 2001;322:1271-4.
Ref ID: 863
- 267 Petty TL. The national mucolytic study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. *Chest* 1990;97:75-83.
Ref ID: 1403
- 268 Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. *Pharmacological Research* 2000;42:39-50.
Ref ID: 922
- 269 MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. *Novartis Found Symp* 2001;234:169-85.
Ref ID: 10055
- 270 Rahman I, MacNee W. Regulation of redox glutathione levels and gene transcription in lung inflammation: therapeutic approaches. *Free Radic Biol Med* 2000;28:1405-20.
Ref ID: 13662
- 271 Rautalahti M, Virtamo J, Haukka J, Heinonen OP, Sundvall J, Albanes D *et al*. The effect of alpha-tocopherol and beta-carotene supplementation on COPD symptoms. *American Journal of Respiratory & Critical Care Medicine* 1997;156:1447-52.
Ref ID: 1449
- 272 The ATBC Cancer Prevention Study Group. The alpha tocopherol, beta carotene lung cancer prevention study: design, methods, participant characteristics, and compliance. *Annals of Epidemiology* 1994;4:1-10.
Ref ID: 1530
- 273 Aversa C, Cazzola M, Clini V, Dal Negro R, Maiorano V, Tana F *et al*. Clinical trial of the efficacy and safety of moguisteine in patients with cough associated with chronic respiratory diseases. *Drugs Under Experimental & Clinical Research* 1993;19:273-9.
Ref ID: 1231
- 274 Barnabe R, Berni F, Clini V, Pirrelli M, Pisani CA, Robusch M *et al*. The efficacy and safety of moguisteine in comparison with codeine phosphate in patients with chronic cough. *Monaldi Archives for Chest Disease* 1995;50:93-7.
Ref ID: 1232
- 275 Del Donno M, Aversa C, Corsico R, Foresi A, Grassi V, Malerba M *et al*. Efficacy and safety of moguisteine in comparison with dextromethorphan in patients with persistent cough. *Drug Investigation* 1994;7:93-100.
Ref ID: 1233

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 276 Sergysels R, Art G. A double-masked, placebo-controlled polysomnographic study of the antitussive effects of helicine. *Current Therapeutic Research, Clinical & Experimental* 2001;**62**:35-47.
Ref ID: 1238
- 277 Wojcicki J, Szwed G, Drozdowska KD. The antitussive and expectorant drug Duopect evaluated by the preferential test. *Archivum Immunologiae et Therapiae Experimentalis* 1976;**24**:549-52.
Ref ID: 80
- 278 Staykova T, Black P, Chacko E, Ram FSF, Poole P. Prophylactic antibiotic therapy for chronic bronchitis. (Cochrane Review). *The Cochrane Library. Oxford: Update Software* 2003;**Issue 3**.
Ref ID: 19362
- 279 Francis R. Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations and their cost. *BMJ* 1960.
Ref ID: 1380
- 280 Gosling, W. R. O., Djajadinigrat, R. J., Bergstein, P. G. M., and Holle, P. Continuous suppressive antimicrobial treatment in chronic infected bronchitis during the winter months. *Diseases of the Chest* (376), 380. 1967.
Ref ID: 19452
- 281 Johnston, R. N., Lockhart, W., Smith, D. H., and Cadman, N. k. A trial of phenethicillin in chronic bronchitis. *BMJ* , 985-986. 1961.
Ref ID: 19453
- 282 Johnston RN, McNeill RS, Smith DH, Dempster MB, Nairn JR, Purvis MS *et al*. Five-year winter chemoprophylaxis for chronic bronchitis. *British Medical Journal* 1969;**4**:265-9.
Ref ID: 1274
- 283 Liippo, K., Pelliniemi, T. T., and Lehto, H. Trimethoprim prophylaxis of acute exacerbations in chronic obstructive pulmonary disease. *Acta Medica Scandinavica* , 455-459. 1987.
Ref ID: 19454
- 284 Moyes, E. N. and Kershaw, R. A. Long-continued treatment with tetracycline and prednisolone in chronic bronchitis. *Lancet* , 1187-1191. 1957.
Ref ID: 19455
- 285 Murdoch, J. McC., Leckie, W. J. H., Downie, J., Swain, R. H. A., and Gould, J. C. An evaluation of continuous antibiotic therapy in chronic bronchitis. *BMJ* , 1277-1285. 1959.
Ref ID: 19456
- 286 Pridie R. A trial of continuous winter chemotherapy in chronic bronchitis. *Lancet* 1960.
Ref ID: 1376
- 287 Working Party of the Medical Research Council. Value of chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Reserach Council by their Working Party on Trials of Chemotherapy in Early Chronic Bronchitis. *BMJ* , 1317-1322. 1966.
Ref ID: 19451
- 288 Haas H, Morris JF, Samson S. Effect of oral penicillin on pneumococcal carriage in elderly men with chronic bronchitis. *Clinical Therapeutics* 1986;**8**:301-8.
Ref ID: 154
- 289 Suzuki T, Yanai M, Yamaya M, Satoh NT, Sekizawa K, Ishida S *et al*. Erythromycin and common cold in COPD. *Chest* 2001;**120**:730-3.
Ref ID: 1148
- 290 MRC, Fletcher. Value of Chemoprophylaxis and chemotherapy in early chronic bronchitis. A report to the Medical Research Council by their working party on trials of chemotherapy in early chronic bronchitis. *BMJ* 1966;**1**:1317-22.
Ref ID: 1317
- 291 Pines A. Controlled trials of a sulphonamide given weekly to prevent exacerbations of chronic bronchitis. *BMJ* 1967.
Ref ID: 1377

- 292 Moher D, Schulz K, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet* 2001;**357**:1191-4.
Ref ID: 19292
- 293 Hahn HH, MacGregor RR, Avent CK, Counts GW, Smith HE, Beaty HN. Ampicillin and tetracycline in the treatment and prophylaxis of chronic bronchitis. *Antimicrobial Agents & Chemotherapy* 1972;**2**:45-8.
Ref ID: 267
- 294 Grob PR, White E, Gargan R, Gibbs FJ. The use of erythromycin as prophylaxis in chronic bronchitis: a cohort study from general practice. *Journal of International Medical Research* 1980;**8**:Suppl 2:47-50.
Ref ID: 1273
- 295 Pugh DL, Holland EE. Chemoprophylaxis in chronic bronchitis. *Antiseptic* 1974;**71**:261-7.
Ref ID: 1278
- 296 McVay L. Antibiotic prophylaxis in chronic respiratory diseases. *Arch Intern Med* 1953;**92**:833-46.
Ref ID: 1370
- 297 Buchanan J. Long-term prophylactic administration of tetracycline to chronic bronchitics. *Lancet* 1958.
Ref ID: 1378
- 298 Cherniack N. Long-term treatment of bronchiectasis and chronic bronchitis. *Archives of Internal Medicine* 1959;**103**:345-53.
Ref ID: 1379
- 299 Francis R. Chemotherapy of bronchitis. Influence of penicillin and tetracycline administered daily, or intermittently for exacerbations. *BMJ* 1961.
Ref ID: 1381
- 300 Cooper J, Inman J, Currie W. Prophylactic treatment of chronic bronchitis comparing cotrimoxazole and amoxycillin. *British Journal of Clinical Practice* 1975;**29**:307-10.
Ref ID: 1382
- 301 Specialist Nurse Innovations for COPD Review. Barts and The London . 2003. www.smd.gmul.ac.uk/gp/copdreview/copdreview.html
Ref ID: 19497
- 302 Smith B, Appleton S, Adams R, Southcott A, Ruffin R. Home care by outreach nursing for chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 1134
- 303 Thomas M, McKinley RK, Freeman E, Foy C, Prodger P, Price D. Breathing retraining for dysfunctional breathing in asthma: a randomised controlled trial. *Thorax* 2003;**58**:110-5.
Ref ID: 19291
- 304 Rivington-Law BA, Epstein SW, Thompson GL, Corey PN. Effect of chest wall vibrations on pulmonary function in chronic bronchitis. *Chest*. 1984;**85**:378-81.
Ref ID: 1353
- 305 Kurabayashi H, Machida I, Tamura K, Iwai F, Tamura J, Kubota K. Breathing out into water during subtotal immersion: A therapy for chronic pulmonary emphysema. *American Journal of Physical Medicine & Rehabilitation* 2000;**79**:150-3.
Ref ID: 1654
- 306 Mohsenifar Z, Rosenberg N, Goldberg HS, Koerner SK. Mechanical vibration and conventional chest physiotherapy in outpatients with stable chronic obstructive lung disease. *Chest* 1985;**87**:483-5.
Ref ID: 1655
- 307 Olseni L, Midgren B, Hornblad Y, Wollmer P. Chest physiotherapy in chronic obstructive pulmonary disease: Forced expiratory technique combined with either postural drainage or positive expiratory pressure breathing. *Respiratory Medicine* 1994;**88** :435-40.
Ref ID: 1656

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 308 Savci S, Ince DI, Arikan H. A comparison of autogenic drainage and the active cycle of breathing techniques in patients with chronic obstructive pulmonary diseases. *Journal of Cardiopulmonary Rehabilitation* 2000;**20**:37-43.
Ref ID: 1658
- 309 Van Hengstum M, Festen J, Beurskens C, Hankel M, Beekman F, Corstens F. Effect of positive expiratory pressure mask physiotherapy (PEP) versus forced expiration technique (FET/PD) on regional lung clearance in chronic bronchitis. *European Respiratory Journal* 1991;**4**:651-4.
Ref ID: 1660
- 310 Kolaczowski W, Taylor R, Hoffstein V. Improvement in oxygen saturation after chest physiotherapy in patients with emphysema. *Physiotherapy Canada* 1989;**41**:18-23.
Ref ID: 1652
- 311 Christensen EF, Nedergaard T, Dahl R. Long-term treatment of chronic bronchitis with positive expiratory pressure mask and chest physiotherapy. *Chest* 1990;**97**:645-50.
Ref ID: 1651
- 312 Casciari RJ, Fairshter RD, Harrison A. Effects of breathing retraining in patients with chronic obstructive pulmonary disease. *Chest* 1981;**79**:393-8.
Ref ID: 1645
- 313 van Ede L, Yzermans CJ, Brouwer HJ. Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. *Thorax* 1999;**54**:688-92.
Ref ID: 877
- 314 Rose C, Wallace L, Dickson R, Ayres J, Lehman R, Searle Y *et al*. The most effective psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive pulmonary disease (COPD): A systematic review. *Patient Education & Counseling* 2002;**47**:311-8.
Ref ID: 1239
- 315 Borson S, McDonald GJ, Gayle T, Deffenbach MPH, Lakshminarayan S, Vantuinen C. Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary-disease. *Psychosomatics* 1992;**33** :190-201.
Ref ID: 121
- 316 Kunik ME, Braun U, Stanley MA, Wristers K, Molinari V, Stoenner D *et al*. One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease. *Psychological Medicine* 2001;**31**:717-23.
Ref ID: 412
- 317 Man GC, Hsu K, Sproule BJ. Effect of alprazolam on exercise and dyspnea in patients with chronic obstructive pulmonary disease. *Chest* 1986;**90**:832-6.
Ref ID: 1566
- 318 Kozora E, Vu TZ, Make B. Neurobehavioral improvement after brief rehabilitation in patients with chronic obstructive pulmonary disease. *Journal of Cardiopulmonary Rehabilitation* 2002;**22**:426-30.
Ref ID: 1563
- 319 van Manen JG, Bindels PJ, Dekker FW, IJzermans CJ, van der Zee JS, Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. *Thorax*. 2002;**57**:412-6.
Ref ID: 1576
- 320 Yohannes AM, Roomi J, Baldwin RC, Connolly MJ. Depression in elderly outpatients with disabling chronic obstructive pulmonary disease. *Age & Ageing* 1998;**27**:155-60.
Ref ID: 1581
- 321 Yohannes AM, Baldwin RC, Connolly MJ. Depression and anxiety in elderly outpatients with chronic obstructive pulmonary disease: Prevalence, and validation of the BASDEC screening questionnaire. *International Journal of Geriatric Psychiatry* 2000;**15**:1090-6.
Ref ID: 1358

- 322 Lacasse Y, Rousseau L, Maltais F. Prevalence of depressive symptoms and depression in patients with severe oxygen-dependent chronic obstructive pulmonary disease. *Journal of Cardiopulmonary Rehabilitation* 2001;**21**:80-6.
Ref ID: 1564
- 323 Crockett AJ, Cranston JM, Moss JR, Alpers JH. The impact of anxiety, depression and living alone in chronic obstructive pulmonary disease. *Quality of Life Research*. 2002;**11**:309-16.
Ref ID: 1553
- 324 Dowson C, Laing R, Barraclough R, Town I, Mulder R, Norris K *et al*. The use of the Hospital Anxiety and Depression Scale (HADS) in patients with chronic obstructive pulmonary disease: a pilot study. *New Zealand Medical Journal*. 2001;**114**:447-9.
Ref ID: 1555
- 325 Withers NJ, Rudkin ST, White RJ. Anxiety and depression in severe chronic obstructive pulmonary disease: The effects of pulmonary rehabilitation. *Journal of Cardiopulmonary Rehabilitation* 1999;**19**:362-5.
Ref ID: 1577
- 326 Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old age. *Age & Ageing*. 2002;**31**:137-40.
Ref ID: 1579
- 327 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr.Scand* 1983;**67**:361-70.
Ref ID: 19293
- 328 Okubadejo AA, Paul EA, Jones PW, Wedzicha JA. Does long-term oxygen therapy affect quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia? *European Respiratory Journal* 1996;**9**:2335-9.
Ref ID: 1761
- 329 Yohannes AM, Connolly MJ, Baldwin RC. A feasibility study of antidepressant drug therapy in depressed elderly patients with chronic obstructive pulmonary disease. *International Journal of Geriatric Psychiatry* 2001;**16**:451-4.
Ref ID: 1102
- 330 Schols AM, Wouters EF. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. *Clin Chest Med* 2000;**21**:753-62.
Ref ID: 850
- 331 Agusti AG. Systemic effects of chronic obstructive pulmonary disease. *Novartis Found Symp* 2001;**234**:242-9.
Ref ID: 341
- 332 Ferreira IM, Brooks D, Lacasse Y, Goldstein RS, White J. Nutritional supplementation for stable chronic obstructive pulmonary disease.(Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 1503
- 333 Otte KE, Ahlburg P, D'Amore F, Stellfeld M. Nutritional repletion in malnourished patients with emphysema. *Journal of Parenteral & Enteral Nutrition* 1989;**13**:152-6.
Ref ID: 289
- 334 Slinde F, Gronberg AM, Engstrom CR, Rossander-Hulthen L, Larsson S. Individual dietary intervention in patients with COPD during multidisciplinary rehabilitation. *Respiratory Medicine*. 2002;**96**:330-6.
Ref ID: 1514
- 335 Schols AMWJ, Mostert R, Soeters PB, Greve LH, Wouters EFM. Nutritional state and exercise performance in patients with chronic obstructive lung disease. *Thorax* 1989;**44**:937-41.
Ref ID: 281
- 336 Baarends EM, Schols AM, Mostert R, Wouters EF. Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. *European Respiratory Journal*. 1997;**10**:2807-13.
Ref ID: 1587

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 337 Engelen MP, Schols AM, Baken WC, Wesseling GJ, Wouters EF. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. *European Respiratory Journal*. 1994;**7**:1793-7.
Ref ID: 1591
- 338 Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine*. 1999;**160**:1856-61.
Ref ID: 1596
- 339 Marquis K, Debigare R, Lacasse Y, LeBlanc P, Jobin J, Carrier G *et al*. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine*. 2002;**166**:809-13.
Ref ID: 1598
- 340 Prescott E, Almdal T, Mikkelsen KL, Tofteng CL, Vestbo J, Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. *European Respiratory Journal*. 2002;**20**:539-44.
Ref ID: 1603
- 341 Sahebjam H, Doers JT, Render ML, Bond TL. Anthropometric and pulmonary function test profiles of outpatients with stable chronic obstructive pulmonary disease. *American Journal of Medicine* 1993;**94**:469-74.
Ref ID: 1605
- 342 Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. *American Review of Respiratory Disease*. 1989;**139**:1435-8.
Ref ID: 1610
- 343 Gray-Donald K, Gibbons L, Shapiro SH, Martin JG. Effect of nutritional status on exercise performance in patients with chronic obstructive pulmonary disease. *American Review of Respiratory Disease*. 1989;**140**:1544-8.
Ref ID: 1613
- 344 Schols AMWJ, Soeters PB, Dingemans AMC, Mostert R, Frantzen PJ, Wouters EFM. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. *American Review of Respiratory Disease* 1993;**147**:1151-6.
Ref ID: 1614
- 345 Sahebjam H, Sathianpitayakul E. Influence of body weight on the severity of dyspnea in chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 2000;**161**:886-90.
Ref ID: 1616
- 346 Schols AMWJ, Slangen J, Volovics L, Wouters EFM. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 1998;**157**:1791-7.
Ref ID: 8
- 347 Palange P, Forte S, Felli A, Galassetti P, Serra P, Carlone S. Nutritional state and exercise tolerance in patients with COPD. *Chest* 1995;**107**:1206-12.
Ref ID: 1601
- 348 Rogers RM, Donahoe M, Costantino J. Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease. A randomized control study. *American Review of Respiratory Disease*. 1992;**146**:1511-7.
Ref ID: 1612
- 349 Koplemann, P. G. and The members of the working party. Nutrition and patients a doctors responsibility. RCP London. 1-97. 2002. London, RCP.
Ref ID: 19472

- 350 Roberts CM, Lowe D, Bucknall CE, Ryland I, Kelly Y, Pearson MG. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. *Thorax* 2002;**57**:137-41.
Ref ID: 19252
- 351 Jennings AL, Davies AN, Higgins JPT, Broadley K. Opioids for the palliation of breathlessness in terminal illness. (Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 1716
- 352 Elkington H, White P, Higgs R, Pettinari CJ. GPs' views of discussions of prognosis in severe COPD. *Family Practice* 2001;**18**:440-4.
Ref ID: 117
- 353 Sullivan KE, Hebert PC, Logan J, O'Connor AM, McNeely PD. What do physicians tell patients with end-stage COPD about intubation and mechanical ventilation? *Chest*. 1996;**109**:258-64.
Ref ID: 1528
- 354 Rhodes P. Focus on palliative care. Palliative care: the situation of people with chronic respiratory disease. *British Journal of Community Nursing* 1999;**4**:131-6.
Ref ID: 1545
- 355 Heffner JE, Fahy B, Hilling L, Barbieri C. Attitudes regarding advance directives among patients in pulmonary rehabilitation. *Am J Respir Crit Care Med* 1996;**154**:1735-40.
Ref ID: 1717
- 356 Ramsdell JW, Henderson S, Renvall MJ, Salmon DP, Ferguson P. Effects of theophylline and ipratropium on cognition in elderly patients with chronic obstructive pulmonary disease. *Annals of Allergy Asthma & Immunology* 1996;**76**:335-40.
Ref ID: 145
- 357 Hunt A. The elderly at home. A study of elderly people living in the community in England in 1976. London: OPCS, 1976.
Ref ID: 19294
- 358 Yohannes AM, Roomi J, Connolly MJ. Elderly people at home disabled by chronic obstructive pulmonary disease. *Age Ageing* 1998;**27**:523-5.
Ref ID: 19295
- 359 Yohannes AM, Greenwood YA, Connolly MJ. Reliability of the Manchester respiratory activities of daily living questionnaire as a postal questionnaire. *Age Ageing* 2002;**31**:355-8.
Ref ID: 19296
- 360 Yohannes AM, Roomi J, Winn S, Connolly MJ. The Manchester Respiratory Activities of Daily Living questionnaire: development, reliability, validity, and responsiveness to pulmonary rehabilitation *J Am Geriatr Soc* 2000;**48**:1496-500.
Ref ID: 19297
- 361 Garrod R, Bestall JC, Paul EA, Wedzicha JA, Jones PW. Development and validation of a standardized measure of activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living scale (LCADL). *Respir Med* 2000;**94**:589-96.
Ref ID: 5650
- 362 Garrod R, Paul EA, Wedzicha JA. An evaluation of the reliability and sensitivity of the London Chest Activity of Daily Living Scale (LCADL). *Respir Med* 2002;**96**:725-30.
Ref ID: 5654
- 363 Law M, Polatajko H, Pollock N, McColl MA, Carswell A, Baptiste S. Pilot testing of the Canadian Occupational Performance Measure: clinical and measurement issues. *Can J Occup Ther* 1994;**61**:191-7.
Ref ID: 9372
- 364 Sewell L, Singh SJ. The Canadian Occupational Performance Measure: Is it a reliable measure in clients with chronic obstructive pulmonary disease? *British Journal of Occupational Therapy*. 2001;**64**:305-10.
Ref ID: 19495

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 365 Managing passengers with respiratory disease planning air travel: British Thoracic Society recommendations. *Thorax* 2002;**57**:289-304.
Ref ID: 19298
- 366 Zaugg M, Kaplan V, Widmer U, Baumann PC, Russi EW. Fatal air embolism in an airplane passenger with a giant intrapulmonary bronchogenic cyst. *Am J Respir Crit Care Med* 1998;**157**:1686-9.
Ref ID: 19299
- 367 Sassi-Dambron DE, Eakin EG, Ries AL, Kaplan RM. Treatment of dyspnea in COPD. A controlled clinical trial of dyspnea management strategies. *Chest* 1995;**107**:724-9.
Ref ID: 62
- 368 Howland J, Nelson EC, Barlow PB, McHugo G, Meier FA, Brent P *et al*. Chronic obstructive airway disease. Impact of health education. *Chest* 1986;**90**:233-8.
Ref ID: 103
- 369 Gallefoss F, Bakke PS, Rsgaard PK. Quality of life assessment after patient education in a randomized controlled study on asthma and chronic obstructive pulmonary disease. *American Journal of Respiratory & Critical Care Medicine* 1999;**159**:812-7.
Ref ID: 113
- 370 Gallefoss F, Bakke PS. How does patient education and self-management among asthmatics and patients with chronic obstructive pulmonary disease affect medication? *American Journal of Respiratory & Critical Care Medicine* 1999;**160**:2000-5.
Ref ID: 114
- 371 Devine EC, Percy J. Meta-analysis of the effects of psychoeducational care in adults with chronic obstructive pulmonary disease. *Patient Education & Counseling* 1996;**29**:167-78.
Ref ID: 78
- 372 Monninkhof EM, van der Valk PDLPM, van der Palen J, Van Herwaarden CLA, Partidge MR, Zielhuis GA. Self-management education for patients with chronic obstructive pulmonary disease (Cochrane review). *The Cochrane Library. Oxford: Update Software* 2003;**Issue 3**.
Ref ID: 436
- 373 Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R *et al*. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease - A disease-specific self- management intervention. *Archives of Internal Medicine* 2003;**163**:585-91.
Ref ID: 1712
- 374 Emery CF, Schein RL, Hauck ER, MacIntyre NR. Psychological and cognitive outcomes of a randomized trial of exercise among patients with chronic obstructive pulmonary disease. *Health Psychology* 1998;**17**:232-40.
Ref ID: 1076
- 375 Blake RL, Jr., Vandiver TA, Braun S, Bertuso DD, Straub V. A randomized controlled evaluation of a psychosocial intervention in adults with chronic lung disease. *Fam. Med* 1990;**22**:365-70.
Ref ID: 1800
- 376 Littlejohns P, Baveystock CM, Parnell H, Jones PW. Randomised controlled trial of the effectiveness of a respiratory health worker in reducing impairment, disability, and handicap due to chronic airflow limitation. *Thorax* 1991;**46**:559-64.
Ref ID: 1801
- 377 Cockcroft A, Bagnall P, Heslop A, Andersson N, Heaton R, Batstone J *et al*. Controlled trial of respiratory health worker visiting patients with chronic respiratory disability. *Br Med J (Clin Res Ed)* 1987;**294**:225-8.
Ref ID: 1803
- 378 Solomon DK, Portner TS, Bass GE, Gourley DR, Gourley GA, Holt JM *et al*. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. *J Am Pharm Assoc (Wash.)* 1998;**38**:574-85.
Ref ID: 1804

- 379 Gourley GA, Portner TS, Gourley DR, Rigolosi EL, Holt JM, Solomon DK *et al*. Humanistic outcomes in the hypertension and COPD arms of a multicenter outcomes study. *J Am Pharm Assoc (Wash.)* 1998;**38**:586-97.
Ref ID: 1805
- 380 Watson PB, Town GI, Holbrook N, Dwan C, Toop LJ, Drennan CJ. Evaluation of a self-management plan for chronic obstructive pulmonary disease. *European Respiratory Journal* 1997;**10**:1267-71.
Ref ID: 1096
- 381 Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with chronic obstructive pulmonary disease. *Respir Med* 2000;**94**:279-87.
Ref ID: 1802
- 382 The Australian Lung Foundation. Chronic Obstructive Pulmonary Disease (COPD). Australian and New Zealand Management Guidelines. 2002. Lutwyche.
Ref ID: 19438
- 383 NCEPOD. Extremes of age. The 1999 report of the national confidential enquiry into perioperative deaths. 1999. London. NCEPOD.
Ref ID: 19304
- 384 Appleberg M, Gordon L, Fatti LP. Preoperative pulmonary evaluation of surgical patients using the vitalograph. *Br J Surg* 1974;**61**:57-9.
Ref ID: 665
- 385 Kocabas A, Kara K, Ozgur G, Sonmez H, Burgut R. Value of preoperative spirometry to predict postoperative pulmonary complications. *Respir Med* 1996;**90**:25-33.
Ref ID: 1807
- 386 Celli BR, Rodriguez KS, Snider GL. A controlled trial of intermittent positive pressure breathing, incentive spirometry, and deep breathing exercises in preventing pulmonary complications after abdominal surgery. *Am Rev Respir Dis* 1984;**130**:12-5.
Ref ID: 2844
- 387 Saklad M. Grading of patients for surgical procedures. *Anesthesiology* 1941;**2**:281-4.
Ref ID: 14590
- 388 Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. *Chest* 2000;**117**:398S-401S.
Ref ID: 30
- 389 Garcia-Aymerich J, Monso E, Marrades RM, Escarrabill J, Felez MA, Sunyer J *et al*. Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation - EFRAM Study. *American Journal of Respiratory and Critical Care Medicine* 2001;**164**:1002-7.
Ref ID: 28
- 390 Connors AF, Dawson NV, Thomas C, Harrell FE, Desbiens N, Fulkerson WJ *et al*. Outcomes following acute exacerbation of severe chronic obstructive lung disease. *American Journal of Respiratory and Critical Care Medicine* 1996;**154**:959-67.
Ref ID: 21
- 391 Seemungal TAR, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 2000;**161**:1608-13.
Ref ID: 6
- 392 Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. *Thorax* 2002; **57**:847-52.
Ref ID: 19253
- 393 Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 1998;**157**:1418-22.
Ref ID: 20

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 394 Andersson F, Borg S, Jansson S-A, Jonsson A-C, Ericsson A, Prutz C *et al*. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). *Respiratory Medicine* 2002;**96**:700-8.
Ref ID: 1365
- 395 Price MJ, Hurrell C. Health care costs of treating exacerbations of COPD. *European Respiratory Journal* 1999;**14**.
Ref ID: 19322
- 396 Wedzicha JA. Exacerbations: etiology and pathophysiologic mechanisms. *Chest* 2002;**121**(5):136S-141S.
Ref ID: 19254
- 397 Gravit JH, Al Rawas OA, Cotton MM, Flanigan U, Irwin A, Stevenson RD. Home treatment of exacerbations of chronic obstructive pulmonary disease by an acute respiratory assessment service. *Lancet* 1998;**351**:1853-5.
Ref ID: 19
- 398 Killen J, Ellis H. Assisted discharge for patients with exacerbations of chronic obstructive pulmonary disease: safe and effective. *Thorax* 2000;**55**:885.
Ref ID: 19439
- 399 Skwarska E, Cohen G, Skwarski KM, Lamb C, Bushell D, Parker S *et al*. Randomised controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. *Thorax* 2000;**55**:907-12.
Ref ID: 221
- 400 Davies L, Wilkinson M, Bonner S, Calverley PM, Angus RM. "Hospital at home" versus hospital care in patients with exacerbations of chronic obstructive pulmonary disease: prospective randomised controlled trial. *BMJ* 2000;**321**:1265-8.
Ref ID: 1059
- 401 Ojoo JC, Moon T, McGlone S, Martin K, Gardiner ED, Greenstone MA *et al*. Patients' and carers' preferences in two models of care for acute exacerbations of COPD: results of a randomised controlled trial. *Thorax* 2002;**57**:167-9.
Ref ID: 1130
- 402 Hernandez C, Casas A, Escarrabill J, Alonso J, Puig-Junoy J, Farrero E *et al*. Home hospitalisation of exacerbated chronic obstructive pulmonary disease patients. *European Respiratory Journal*. 2003;**21**:58-67.
Ref ID: 19473
- 403 Fried TR, Van Doorn C, Tinetti ME, Drickamer MA. Older persons' preferences for site of treatment in acute illness. *Journal of General Internal Medicine* 1998;**13**:522-7.
Ref ID: 1126
- 404 Fried TR, Van Doorn C, O'Leary JR, Tinetti ME, Drickamer MA. Older persons' preferences for home vs hospital care in the treatment of acute illness. *Archives of Internal Medicine* 2000;**160**:1501-6.
Ref ID: 1127
- 405 Cotton MM, Bucknall CE, Dagg KD, Johnson MK, MacGregor G, Stewart C *et al*. Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. *Thorax* 2000;**55**:902-6.
Ref ID: 220
- 406 Shepperd S, Harwood D, Jenkinson C, Gray A, Vessey M, Morgan P. Randomised controlled trial comparing hospital at home care with inpatient hospital care. I: three month follow up of health outcomes. *British Medical Journal* 1998;**316**:1786-91.
Ref ID: 838
- 407 Turner MO, Patel A, Ginsburg S, FitzGerald JM. Bronchodilator delivery in acute airflow obstruction: A meta-analysis. *Archives of Internal Medicine* 1997;**157**:1736-44.
Ref ID: 945
- 408 McCrory, D. C., Brown, C., Gray, R. N., Goslin, R. E., MacIntyre, N. R., Kolimaga, J. T., Oddone, E. Z., and Matchar, D. Management of acute exacerbations of chronic obstructive pulmonary disease. 256. 2001. Rockville, MD, USA, Agency for Healthcare Research and Quality.
Ref ID: 1145

- 409 Wood-Baker R, Walters EH, Gibson P. Oral corticosteroids for acute exacerbations of chronic obstructive pulmonary disease (Cochrane Review). *The Cochrane Library.Oxford:Update Software* 2003;**Issue 3**.
Ref ID: 1364
- 410 Singh JM, Palda VA, Stanbrook MB, Chapman KR. Corticosteroid therapy for pts with acute exacerbations of COPD: a systematic review. *Archives of Internal Medicine* 2002;**162**:2527-36.
Ref ID: 1484
- 411 Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. *American Journal of Emergency Medicine*. 1996;**14**:139-43.
Ref ID: 1360
- 412 Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J *et al*. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: A randomized controlled trial. *American Journal of Respiratory & Critical Care Medicine* 2002;**165**:698-703.
Ref ID: 1362
- 413 Davies L, Angus RM, Calverley PMA. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. *Lancet* 1999;**354**:456-60.
Ref ID: 217
- 414 Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW *et al*. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. *New England Journal of Medicine* 1999;**340**:1941-7.
Ref ID: 36
- 415 Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. *American Journal of Respiratory and Critical Care Medicine* 1996;**154**:407-12.
Ref ID: 38
- 416 Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. *Annals of Internal Medicine*. 1980;**92**:753-8.
Ref ID: 1359
- 417 Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. *Chest* 2000;**117**:1638-45.
Ref ID: 17
- 418 SIGN. Community Management of Lower Respiratory Tract Infection in Adults. SIGN publication No 59. 2002. SIGN.
Ref ID: 1316
- 419 Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary-disease exacerbations - a metaanalysis. *Journal of the American Medical Association* 1995;**273**:957-60.
Ref ID: 44
- 420 Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: A randomised placebo-controlled trial. *Lancet* 2001;**358**(9298):2020-2025.
Ref ID: 349
- 421 Sin DD, Tu JV. Outpatient antibiotic therapy and short term mortality in elderly patients with chronic obstructive pulmonary disease. *Canadian Respiratory Journal* 2000;**7**:466-71.
Ref ID: 416
- 422 Allegra L, Blasi F, de Bernardi B, Cosentini R, Tarsia P. Antibiotic treatment and baseline severity of disease in acute exacerbations of chronic bronchitis: a re-evaluation of previously published data of a placebo-controlled randomized study. *Pulmonary Pharmacology & Therapeutics* 2001;**14**:149-55.
Ref ID: 1151

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 423 Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA. Antibiotic-therapy in exacerbations of chronic obstructive pulmonary-disease. *Annals of Internal Medicine* 1987;**106**:196-204.
Ref ID: 25
- 424 Elmes PC, King TK, Langlands JH, Mackay JA, Wallace WF, Wade OL *et al.* Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. *British Medical Journal* 1965;**5467**:904-8.
Ref ID: 1153
- 425 Berry DG, Fry J, Hindley CP. Exacerbations of chronic bronchitis: treatment with oxytetracycline. *Lancet* 1960;**1**:137-9.
Ref ID: 19275
- 426 Davies BI, Maesen FP. Quinolones in chest infections. *J Antimicrob. Chemother.* 1986;**18**:296-9.
Ref ID: 19277
- 427 Morris S, Anderson P, Irwin DE. Acute exacerbations of chronic bronchitis: a pharmaco-economic review of antibacterial use. *Pharmacoeconomics* 2002;**20**:153-68.
Ref ID: 19271
- 428 Backhouse R, Shakespeare A, Hutton J. Economic evaluation of alternative antibiotic regimens in the management of acute exacerbations of chronic bronchitis. *British Journal of Medical Economics* 1995;**8**:1-25.
Ref ID: 19272
- 429 Torrance G, Walker V, Grossman R, Mukherjee J, Vaughan D, La Forge J *et al.* Economic evaluation of ciprofloxacin compared with usual antibacterial care for the treatment of acute exacerbations of chronic bronchitis in patients followed for 1 year. *Pharmacoeconomics* 1999;**16**:499-520.
Ref ID: 19273
- 430 Lakshminarayan S, Sahn SA, Weil JV. Effect of aminophylline on ventilatory responses in normal man. *Am Rev Respir Dis* 1978;**117**:33-8.
Ref ID: 19440
- 431 Sanders JS, Berman TM, Bartlett MM, Kronenberg RS. Increased hypoxic ventilatory drive due to administration of aminophylline in normal men. *Chest* 1980;**78**:279-82.
Ref ID: 19441
- 432 Sharp JT. Theophylline in chronic obstructive pulmonary disease. *Journal Allergy Clin Immunol* 1986;**78**:800-5.
Ref ID: 19442
- 433 Barr RG, Rowe BH, Camargo CA, Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library. Oxford: Update Software* 2003;**Issue 3**.
Ref ID: 859
- 434 Murata GH, Gorby MS, Chick TW, Halperin AK. Aminophylline in the outpatient management of decompensated chronic obstructive pulmonary disease. *Chest* 1990;**98**:1346-50.
Ref ID: 93
- 435 Murciano D, Auclair MH, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary-disease. *New England Journal of Medicine* 1989;**320**:1521-5.
Ref ID: 201
- 436 Barbera JA, Reyes A, Roca J, Montserrat JM, Wagner PD, Rodriguez RR. Effect of intravenously administered aminophylline on ventilation/perfusion inequality during recovery from exacerbations of chronic obstructive pulmonary disease. *American Review of Respiratory Disease* 1992;**145**:1328-33.
Ref ID: 1106
- 437 Rice KL, Leatherman JW, Duane PG, Snyder LS, Harmon KR, Abel J *et al.* Aminophylline for acute exacerbations of chronic obstructive pulmonary disease. A controlled trial. *Annals of Internal Medicine* 1987;**107**:305-9.
Ref ID: 1110

- 438 Seidenfeld JJ, Jones WN, Moss RE, Tremper J. Intravenous aminophylline in the treatment of acute bronchospastic exacerbations of chronic obstructive pulmonary disease. *Ann Emerg Med* 1984;**13**:248-52. Ref ID: 1111
- 439 Wrenn K, Slovis CM, Murphey F, Greenburg RS. Aminophylline therapy for acute bronchospastic disease in the emergency room. *Annals of Internal Medicine* 1991;**115**:241-7. Ref ID: 1289
- 440 Ram, F. S. F., Poole, P. J., Bagg, W., Stewart, J., and Black, P. N. Randomised, controlled trial of theophylline for the treatment of exacerbations of chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 161 Suppl, A489. 2000. Ref ID: 19447
- 441 Greenstone M, Lasserson T. Doxapram for ventilatory failure due to exacerbations of chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library*. Chichester, UK : John Wiley & Sons, Ltd 2003;(4). Ref ID: 1290
- 442 Bardsley PA, Tweney J, Morgan N, Howard P. Oral almitrine in treatment of acute respiratory failure and cor pulmonale in patients with an exacerbation of chronic obstructive airways disease. *Thorax* 1991;**46**:493-8. Ref ID: 1334
- 443 Moser K. Respiratory stimulation with intravenous doxapram in respiratory failure. A double blind cooperative study. *New England Journal of Medicine* 1973;**288**:427-31. Ref ID: 1320
- 444 Angus RM, Ahmed AA, Fenwick LJ, Peacock AJ. Comparison of the acute effects on gas exchange of nasal ventilation and doxapram in exacerbations of chronic obstructive pulmonary disease. *Thorax* 1996;**51**:1048-50. Ref ID: 1293
- 445 Edwards. A double blind trial of five respiratory stimulants in patients with acute ventilation failure. *Lancet* 1967;**2**:226-9. Ref ID: 1319
- 446 Newman, W. J, Banham, S. J, Barr, J., Bell, D., Douglas, N. J., and Innes, A. J. A randomised trial comparing non-invasive ventilation with the respiratory stimulant, doxapram, in the treatment of acute hypercapnic respiratory failure complicating exacerbations of chronic obstructive pulmonary disease. 2001. (Unpublished data). Ref ID: 19477
- 447 Murphy R, Driscoll P, O'Driscoll R. Emergency oxygen therapy for the COPD patient. *Emergency Medicine Journal* 2001;**18**:333-9. Ref ID: 1162
- 448 Murphy R, Mackway-Jones K, Sammy I, Driscoll P, Gray A, O'Driscoll R. Emergency oxygen therapy for the breathless patient. Guidelines prepared by the North West Oxygen Group. *Emergency Medicine Journal* 2001;**18**:421-3. Ref ID: 19443
- 449 Hutchison DCS, Flenley DC, Donald KW. Controlled oxygen therapy in respiratory failure. *BMJ* 1964;**2**:1159-66. Ref ID: 19307
- 450 Bone RC, Pierce AK, Johnson RL, Jr. Controlled oxygen administration in acute respiratory failure in chronic obstructive pulmonary disease: a reappraisal. *Am J Med* 1978;**65**:896-902. Ref ID: 19309
- 451 Agusti AG, Carrera M, Barbe F, Munoz A, Togores B. Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. *Eur Respir J* 1999;**14**:934-9. Ref ID: 19310

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 452 King TK, Ali N, Briscoe WA. Treatment of hypoxia with 24 percent oxygen. A new approach to the interpretation of data collected in a pulmonary intensive care unit. *Am Rev Respir Dis* 1973;**108**:19-29.
Ref ID: 19312
- 453 Plant PK, Owen JL, Elliott MW. One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. *Thorax* 2000;**55**:550-4.
Ref ID: 13275
- 454 DeGaute JP, Domenighetti G, Naeije R, Vincent JL, Treyvaud D, Perret C. Oxygen delivery in acute exacerbation of chronic obstructive pulmonary disease. Effects of controlled oxygen therapy. *Am Rev Respir Dis* 1981;**124**:26-30.
Ref ID: 4042
- 455 Smith JP, Stone RW, Muschenheim C. Acute respiratory failure in chronic lung disease. *American Review of Respiratory Disease*. 1968;**97**:791-803.
Ref ID: 19315
- 456 Eldridge F, Gherman C. Studies of oxygen administration in respiratory failure. *Ann Intern Med* 1968;**68**:569-78.
Ref ID: 4657
- 457 Prime FJ, Westlake EK. The respiratory response to CO₂ in emphysema. *Clin Sci* 1954;**13**:321-32.
Ref ID: 17344
- 458 Aubier M, Murciano D, Milic-Emili J, Touaty E, Daghfous J, Pariente R *et al*. Effects of the administration of O₂ on ventilation and blood gases in patients with chronic obstructive pulmonary disease during acute respiratory failure. *Am Rev Respir Dis* 1980;**122**:747-54.
Ref ID: 781
- 459 Fajac I, Texereau J, Rivoal V, Dessanges JF, Dinh-Xuan AT, Dall'Ava-Santucci J. Blood gas measurement during exercise: a comparative study between arterialized earlobe sampling and direct arterial puncture in adults. *Eur Respir J* 1998;**11**:712-5.
Ref ID: 4961
- 460 Dall'Ava-Santucci J, Dessanges JF, Dinh Xuan AT, Lockhart A. Is arterialized earlobe blood PO₂ an acceptable substitute for arterial blood PO₂? *Eur Respir J* 1996;**9**:1329-30.
Ref ID: 3791
- 461 Pitkin AD, Roberts CM, Wedzicha JA. Arterialised earlobe blood gas analysis: an underused technique. *Thorax* 1994;**49**:364-6.
Ref ID: 13267
- 462 Sauty A, Uldry C, Debetaz LF, Leuenberger P, Fitting JW. Differences in PO₂ and PCO₂ between arterial and arterialized earlobe samples. *Eur Respir J* 1996;**9**:186-9.
Ref ID: 19320
- 463 Peter JV, Moran JL, Phillips-Hughes J, Warn D. Noninvasive ventilation in acute respiratory failure—a meta-analysis update. *Critical Care Medicine*. 2002;**30**:555-62.
Ref ID: 854
- 464 Keenan SP, Kernerman PD, Cook DJ, Martin CM, McCormack D, Sibbald WJ. Effect of noninvasive positive pressure ventilation on mortality in patients admitted with acute respiratory failure: a meta-analysis. *Critical Care Medicine* 1997;**25**:1685-92.
Ref ID: 887
- 465 Ram FSF, Lightowler JVJ, Wedzicha JA. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. (Cochrane Review). *The Cochrane Library. Oxford: Update Software* 2003;**Issue 3**.
Ref ID: 1485

- 466 Thys F, Roeseler J, Reynaert M, Liistro G, Rodenstein DO. Noninvasive ventilation for acute respiratory failure: A prospective randomised placebo-controlled trial. *European Respiratory Journal* 2002;**20**:545-55. Ref ID: 1314
- 467 Conti G, Antonelli M, Navalesi P. Noninvasive vs conventional mechanical ventilation in pts with COPD after failure of medical treatment in the ward; a randomised trial. *Intensive Care Medicine* 2002;**28**:1701-7. Ref ID: 1486
- 468 Keenan SP, Gregor J, Sibbald WJ, Cook D, Gafni A. Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. *Critical Care Medicine* 2000;**28**:2094-102. Ref ID: 871
- 469 Plant PK, Owen JL, Parrott S, Elliott MW. Cost effectiveness of ward based non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: economic analysis of randomised controlled trial. *BMJ* 2003;**326**:956. Ref ID: 19323
- 470 Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. *JAMA* 1995;**274**:1852-7. Ref ID: 115
- 471 Esteban A, Anzueto A, Frutos F, Alia I, Brochard L, Stewart TE *et al.* Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. *JAMA* 2002;**287**:345-55. Ref ID: 1307
- 472 Rieves RD, Bass D, Carter RR, Griffith JE, Norman JR. Severe COPD and acute respiratory failure. Correlates for survival at the time of tracheal intubation. *Chest* 1993;**104**:854-60. Ref ID: 1487
- 473 Nevins ML, Epstein SK. Predictors of outcome for patients with COPD requiring invasive mechanical ventilation. *Chest* 2001;**119**:1840-9. Ref ID: 1488
- 474 Nava S, Ambrosino N, Clini E, Prato M, Orlando G, Vitacca M *et al.* Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to chronic obstructive pulmonary disease. A randomized, controlled trial. *Annals of Internal Medicine* 1998;**128**:721-8. Ref ID: 1311
- 475 Jones AP, Rowe BH. Bronchopulmonary hygiene physical therapy for chronic obstructive pulmonary disease and bronchiectasis (Cochrane Review). *The Cochrane Library. Oxford: Update Software* 2003;**Issue 3**. Ref ID: 1345
- 476 Bellone A, Laschi S, Raschi S, Guzzi L, Adone R. Chest physical therapy in patients with acute exacerbation of chronic bronchitis: Effectiveness of three methods. *Archives of Physical Medicine & Rehabilitation* 2000;**81**:558-60. Ref ID: 1338
- 477 Newton DA, Bevans HG. Physiotherapy and intermittent positive-pressure ventilation of chronic bronchitis. *British Medical Journal*. 1978;**2**:1525-8. Ref ID: 1341
- 478 Bellone A, Spagnolatti L, Massobrio M, Bellei E, Vinciguerra R, Barbieri A *et al.* Short-term effects of expiration under positive pressure in patients with acute exacerbation of chronic obstructive pulmonary disease and mild acidosis requiring non-invasive positive pressure ventilation. *Intensive Care Medicine* 2002;**28**:581-5. Ref ID: 1342
- 479 Wollmer P, Ursing K, Midgren B, Eriksson L. Inefficiency of chest percussion in the physical therapy of chronic bronchitis. *European Journal of Respiratory Diseases* 1985;**66**:233-9. Ref ID: 1344

Chronic Obstructive Pulmonary Disease: National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care

- 480 Brown PM, Manfreda J, McCarthy D, MacDonald S. The effect of mechanical vibration in patients with acute exacerbations of COPD. *Physiotherapy Canada* 1987;**39**:371-4.
Ref ID: 1497
- 481 National COPD audit. Royal College of Physicians . 2003.
Ref ID: 19461
- 482 Fletcher C., Peto R. The natural history of chronic airflow obstruction. *BMJ* 1977;**1**:1645-8.
Ref ID: 19444
- 483 Harper R, Brazier J E, Waterhouse J C, Walters S J, Jones N M B, Howard P. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. *Thorax* 1997;**52**:879-87.
Ref ID: 19445
- 484 Netten, A. and Curtis, L. Unit Costs of Health and Social Care. 2003. PSSRU. The University of Kent.
Ref ID: 19448
- 485 Guest JF. The annual cost of chronic obstructive pulmonary disease to the UK's National Health Service. *Disease Management and Health Outcomes* 1999;**5**:2-100.
Ref ID: 19446
- 486 Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. *Chest* 2000;**117**:5S-9S.
Ref ID: 19338
- 487 Calverley, P. and Sondhi, S. The burden of obstructive lung disease in the UK - COPD and asthma. *Thorax*. 1996.
Ref ID: 19305
- 488 The Department of Health, NHS executive. Burdens of Disease, A discussion document. 1996. London. The Department of Health.
Ref ID: 19344
- 489 Gibson PG, Wlodarczyk JH, Wilson AJ, Sprogis A. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. *J Qual Clin Pract* 1998;**18**:125-33.
Ref ID: 19318
- 490 McGuire A, Irwin DE, Fenn P, Gray A, Anderson P, Lovering A *et al*. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. *Value Health* 2001;**4**:370-5.
Ref ID: 19327
- 491 Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. *Lancet* 2000; **355**:1931-1935.



Reference list

Thorax 2004 59: i199-i232

Updated information and services can be found at:
http://thorax.bmj.com/content/59/suppl_1/i199.citation

These include:

**Email alerting
service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>